
Drugmaker backpedals on specialty status for COVID-19 drug
Facing public criticism, the maker of a promising coronavirus drug said Wednesday it will waive a special regulatory designation that could have allowed it to block competition and boost profits for its treatment.
Mar 25, 2020
0
0